Sukumar Nagendran
President bei TAYSHA GENE THERAPIES, INC.
Vermögen: 153 507 $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Sean Nolan | M | 56 | 10 Jahre | |
| Philip Donenberg | M | 63 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 9 Jahre |
| James Davis | M | 61 | 11 Jahre | |
| Ilan Ganot | M | 50 | 11 Jahre | |
| Joseph Higgins | M | - |
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 4 Jahre |
| Raj Agarwal | M | - |
Medocity, Inc.
 Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | - |
| Rachel McMinn | M | 51 |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 6 Jahre |
| Alexander Cumbo | M | 53 | 2 Jahre | |
| Adam Koppel | M | 54 | 7 Jahre | |
| Masahiko Ohtsuki | M | 64 | 14 Jahre | |
| Kamran Alam | M | 46 | 8 Jahre | |
| TY Howton | M | 52 | 2 Jahre | |
| Sean Stalfort | M | 54 |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 1 Jahre |
| Timothy Main | M | 66 | 10 Jahre | |
| Laura Sepp-Lorenzino | M | 63 | 4 Jahre | |
| Lynne Sullivan | F | 58 | 9 Jahre | |
| Jason Cole | M | 51 |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 1 Jahre |
| Christine Mikail, | - | - |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 5 Jahre |
| Christine Cvijic | F | 46 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 5 Jahre |
| Georgia Keresty | M | 62 | 3 Jahre | |
| Clare Khan | M | 72 | 3 Jahre | |
| Pankaj Bhargava | M | 54 |
Medocity, Inc.
Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | 10 Jahre |
| Adam Stone | M | 44 | 9 Jahre | |
| Raj Shah | M | 46 | 7 Jahre | |
| Martin Freed | M | 63 | 6 Jahre | |
| Vicky Gregg | F | 69 | 10 Jahre | |
| Ian Smith | M | 58 | 4 Jahre | |
| Fred Porter | M | - | - | |
| Annie Ganot | F | - | 11 Jahre | |
| Allison Bogosian | F | - | 3 Jahre | |
| Paul Herzich | M | 46 | 2 Jahre | |
| Sean McAuliffe | M | - | 4 Jahre | |
| Jessie Hanrahan | M | 47 | 2 Jahre | |
| Alison Long | M | 61 | 1 Jahre | |
| Jenny Marlowe | M | 47 | 1 Jahre | |
| Hayleigh Collins | M | - | - | |
| Shuli Kulak | M | - | - | |
| Craig Gordon | M | - |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
| Paula A. Tallal | M | 76 |
Rutgers State University of New Jersey
| 36 Jahre |
| Kevin Tan | M | 46 | 1 Jahre | |
| Pat Sacco | M | - |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 2 Jahre |
| Emily McGinnis | F | - | 4 Jahre | |
| Tracy M. Porter | F | - | 3 Jahre | |
| Arvind Sreedharan | M | - |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | - |
| Cory Freedland | M | 48 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | - |
| Doug Lang | M | - | 11 Jahre | |
| Jim Rouse | M | - | - | |
| Mary Newman | F | 65 | 3 Jahre | |
| Robert Baffi | M | 68 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 4 Jahre |
| Gabriel Brooks | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| R. Session | M | 45 | 6 Jahre | |
| Paul Manning | M | 68 | 8 Jahre | |
| Joel Schneider | M | 39 | 8 Jahre | |
| Stephen DiPalma | M | 66 | 2 Jahre | |
| Matthew Bennett Arnold | M | 55 | 8 Jahre | |
| Timothy Boris | M | 55 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 4 Jahre |
| Rod Wong | M | 47 | 1 Jahre | |
| Kim Lee | M | - | - | |
| Satoru Kimura | M | 66 | - | |
| Ryuzo Takada | M | 78 | - | |
| Alex Greyserman | M | - |
Rutgers State University of New Jersey
| 9 Jahre |
| Alice Lee | F | 53 | - | |
| Lynette Herscha | F | 52 | - | |
| Jennifer Ziolkowski | F | 50 | 4 Jahre | |
| Joel Marc Kallman | M | - |
Rutgers State University of New Jersey
| - |
| Michael B. Johannesen | M | - | 3 Jahre | |
| Julius Mokrauer | M | - |
Rutgers State University of New Jersey
| 4 Jahre |
| George Rusnak | M | - |
Rutgers State University of New Jersey
| 12 Jahre |
| Lisa Deschamps | F | 52 | 3 Jahre | |
| Erin Brennan | M | 53 | 1 Jahre | |
| Claire Aldridge | M | - | 1 Jahre | |
| Kathleen Reape | M | 58 | 3 Jahre | |
| Caitlin Lowie | F | - | 1 Jahre | |
| Andrew Knudten | M | - | - | |
| Hemant Pande | M | - |
Rutgers State University of New Jersey
| 3 Jahre |
| Toshiaki Tojo | M | 68 | 10 Jahre | |
| Eric Floyd | M | 62 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | - |
| Yael Schwartz | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 1 Jahre |
| H. S. Wang | M | - |
Rutgers State University of New Jersey
| 4 Jahre |
| Daniel Welch | M | 66 | 2 Jahre | |
| Stephen Simes | M | 72 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Jerold Howard Rubinstein | M | 86 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 Jahre |
| William F. Buehler | M | 84 | 16 Jahre | |
| Jeffrey Leiden | M | 68 | 5 Jahre | |
| Robert Hagemann | M | 67 | 17 Jahre | |
| Jonathan Leff | M | 55 | 3 Jahre | |
| Carole Nüchterlein | F | 63 | 3 Jahre | |
| John Harkey | M | 63 | 5 Jahre | |
| Terrence Kearney | M | 69 | 2 Jahre | |
| David Sherris | M | 71 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Rex Bright | M | 84 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 Jahre |
| Andrey Zarur | M | 54 | 7 Jahre | |
| Frank Verwiel | M | 62 | 3 Jahre | |
| James Terlizzi | M | 59 |
Rutgers State University of New Jersey
| 7 Jahre |
| John Blair Cummings | M | - |
Rutgers State University of New Jersey
| 11 Jahre |
| Naveen Yalamanchi | M | 47 | - | |
| Zhaobo Wang | M | 67 |
Rutgers State University of New Jersey
| 4 Jahre |
| Bong Koh | M | - | - | |
| Timothy J. Douros | M | - | - | |
| Josiah Craver | M | - | 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 96 | 96,00% |
| Japan | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sukumar Nagendran
- Persönliches Netzwerk
